npj Regenerative Medicine (Feb 2022)

CDH18 is a fetal epicardial biomarker regulating differentiation towards vascular smooth muscle cells

  • Julia Junghof,
  • Yuta Kogure,
  • Tian Yu,
  • Eva María Verdugo-Sivianes,
  • Megumi Narita,
  • Antonio Lucena-Cacace,
  • Yoshinori Yoshida

DOI
https://doi.org/10.1038/s41536-022-00207-w
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 14

Abstract

Read online

Abstract The epicardium is a mesothelial layer covering the myocardium serving as a progenitor source during cardiac development. The epicardium reactivates upon cardiac injury supporting cardiac repair and regeneration. Fine-tuned balanced signaling regulates cell plasticity and cell-fate decisions of epicardial-derived cells (EPCDs) via epicardial-to-mesenchymal transition (EMT). However, powerful tools to investigate epicardial function, including markers with pivotal roles in developmental signaling, are still lacking. Here, we recapitulated epicardiogenesis using human induced pluripotent stem cells (hiPSCs) and identified type II classical cadherin CDH18 as a biomarker defining lineage specification in human active epicardium. The loss of CDH18 led to the onset of EMT and specific differentiation towards cardiac smooth muscle cells. Furthermore, GATA4 regulated epicardial CDH18 expression. These results highlight the importance of tracing CDH18 expression in hiPSC-derived epicardial cells, providing a model for investigating epicardial function in human development and disease and enabling new possibilities for regenerative medicine.